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unreliable for the estimation of GFR. The patients most often 
collected the 24 hour urine on an outpatient basis, and we believe 
that these unsatisfactory results can be caused by imprecise 
urine collection. 
It is evident from the present study and the above mentioned 
reports that the combination regimens of platinum and podo- 
phyllin derivatives can produce high response rates in the 
treatment of extensive SCLC, but it is rather disappointing that 
response duration and survival time remain very short. A 
possible step forward could be dose intensification combined 
with haematopoietic growth factors. 
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Ifosfamide in Advanced Adenocarcinoma of the 
Oesophagus or Oesophageal-Gastric Junction 
Area 
Tjebbe C. Kok, Ate van der Gaast, Ted A.W. Splinter and Huug W. Tilanus 
for the Rotterdam Esophageal Tumor Study Group 
25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or 
oesophageal-gastric junction area were treated with ifosfamide 6 g/m’ over 48 hours, combined with mesna 
6 g/m’. 1 complete response and 1 partial response were seen among 23 patients evaluable, with a response 
duration of 29+ months and 7 months, respectively. Toxicity was not severe: grade 3 infection in 2 patients, 
grade 3 leucopenia in 3 patients and grade 3 nausea in 4 patients. No life-threatening episodes or central nervous 
system toxicity were encountered. Ifosfamide has limited activity in adenocarcinoma of the oesophageal-gastric 
junction area. 
EurJ Cancer, Vol. 27, No. 9, pp. 1112-l 114,1991. 
INTRODUCTION PATIENTS AND METHODS 
THE OUTLOOK for patients with adenocarcinoma of the oesoph- 
agus is dismal; in about 40% metastatic disease is apparent at 
first presentation. Even if a patient is operable, the 5-year 
survival after surgery with curative intent is < 10%. Most of 
these patients die with distant metastases. Obviously, there is a 
need for effective chemotherapy. We investigated the activity 
and toxicity of ifosfamide. 
Until July 1990,25 consecutive previously untreated patients 
were entered in the study. The main eligibility criteria were 
histologically proven adenocarcinoma of the oesophagus or 
oesophageal-gastric junction area, with or without Barrett’s 
epithelium (patients with adenocarcinoma of the gastric cardia, 
without involvement of the oesophageal-gastric junction area 
were not eligible); performance status (Karnofsky) > 60% and 
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Table 1. Characteristics of 23 evaluable patients 
Male/female 
Median age (yr) 
Median performance (Karnofsky) 
Extent of disease 
Locally advanced 
Primary excised, metastases 
2112 
55 (30-74) 
80 (60-lOO)% 
2 
4 
Intra-abdominal 1 
Liver 1 
Pleural 1 
Skin 1 
Primary plus metasfases 17 
Intra-abdominal 2 
Liver 6 
Lymph-node 9 
Median weight loss 10% 
< 1% 1 
l-S% 4 
6-10% 7 
> 10% 11 
a life expectancy of 3 months or more; age 75 years or less; no 
prior chemotherapy; no symptomatic brain metastases; adequate 
bone marrow and kidney function (clearance > 60 mumin); 
measurable disease-if the primary tumour was the only marker 
lesion and not previously irradiated, the disease was considered 
evaluable and monitored by barium radiogram, computed tom- 
ography and endoscopy with biopsies; and a guaranteed food 
intake (in cases of severe stenosis, a prosthetic intubation 
was performed). Patients with a probability of < 0.05 of not 
developing severe CNS toxicity after ifosfamide/mesna infusion, 
calculated by means of serum albumin and creatinine concen- 
tration according to the monogram described by Meanwell et al. 
[l], were not eligible. 
Treatment consisted of prehydration with 500 ml saline 0.9% 
for 2 h followed by 200 ml mannitol20% over 30 min and mesna 
1 g/m2 intravenously. Ifosfamide was given as a 48 h infusion in 
a total dose of 6 g/m2 together with 6000 ml dextrose/saline and 
mesna 3 g/m2. Posthydration was given with 2500 ml dex- 
trose/saline over 16 h together with mesna 2 g/m’. Courses were 
repeated every 4 weeks. Patients were evaluable for response 
after two courses, and evaluable for toxicity after one course. In 
cases of clear progression after the first course, the response was 
evaluated as early progression. In cases of stable disease after 
any two cycles, treatment was stopped. The maximal duration 
of treatment was six cycles or until progression of disease or 
intolerable toxicity, physical or mental. The recommended 
guidelines for the criteria of evaluation and toxic effects proposed 
by the WHO (1979) [2] were followed. Blood counts were 
performed weekly. 
RESULTS 0 I II III IV 
Of 25 entered patients, 1 was not eligible (adenocarcinoma of 
the gastric cardia without involvement of the oesophageal- 
gastric junction area) and 1 was not evaluable for response 
WBC 13 2 6 3 
Infection 22 2 
Plarelets 24 
Nausea, vomiting 1 6 13 4 
Hair 3 15 6 
Neurotoxicity 24 
Renal 23 1 
Cutaneous 23 1 
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Table 2. Tumour characteristics (n = 23) 
Adenocarcinoma in Barrett’s epithelium 4 
Signet-ring cell carcinoma in Barrett’s epithelium 2 
Grade of malignancy (ICD-0) 
Grade 2 15 
Grade 3 7 
Unknown 1 
Location of primary tumour 
Lower oesophagus with junction area 9 
Lower oesophagus with junction area and cardia 10 
Junction area plus cardia 2 
Unknown 2 
(no response evaluation after the second course). The main 
characteristics of 23 evaluable patients are shown in Table 1; 
tumour characteristics are shown in Table 2. Most patients were 
men with a fair performance status, notwithstanding a significant 
weight loss, who had metastatic cancer at first presentation. 
Toxicity data of 24 patients are shown in Table 3, graded 
according to WHO criteria (1979). Of a total of 63 courses, the 
median number was only two. There was no treatment delay 
because of cytopenia; only once did a leucocyte nadir of 1.1 in 
combination with fever require a dose reduction of 25% for the 
next courses. In 2 cases a serious infection (WHO grade 3) 
required hospital admission for intravenous antibiotic therapy 
(WBC nadir 1.7 and 1.1 x 109/1). No serious renal toxicity nor 
any CNS toxicity were seen during the study. Reasons for going 
off study were: serious subjective toxicity (n = l), progressive 
disease during treatment (ll), stable disease after two courses 
(7) and end of protocol treatment (4). 1 patient experienced 
rapid deterioration of his condition after the first course: no 
response evaluation was done. 
Among 23 patients evaluable for response, 1 achieved a 
complete response (CR: response duration 29+ months) and 1 a 
partial response (PR: response duration 7 months). 
The patient who achieved a CR was a 47-year-old man, with a 
Table 3. Toxicity profile (n = 24) 
Total courses 
Median courses 
Dose reduction 
Treatment delay (cytcpenia) 
Median WBC nadir 
Median platelet nadir 
Toxic death 
63 
2 (l-6) 
lx 
ox 
4.0(1.1-6.3)x lO’/l 
262 (174-571) x lo911 
0 
WHO grades 
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poorly differentiated adenocarcinoma in Barrett’s epithelium 
and microscopically proven metastatic lymph-nodes in the coel- 
iac region at laparotomy. He refused surgical treatment after six 
courses of chemotherapy, and is now, 24 years later, in perfect 
condition without clinically detectable tumour (endoscopy plus 
biopsies). The median survival time of all evaluable patients was 
7 months (range 2-54) after start of treatment and 3.5 months 
after stopping chemotherapy. 3 patients are still alive, with a 
follow-up of 2, 3 and 24 + months, respectively, after stopping 
treatment. 
ing the dose and schedule of ifosfamide, we administered 6 g/m* 
as a continuous infusion over 48 h instead of 7.5 g/m2 over 5 
days as daily short intravenous infusions. On the other hand, 
our data on bone marrow suppression are not different from 
those of Ansell et al., and clearly less serious than those of Nanus 
et al., who experienced 18 episodes of WBC count nadir < 1000 
in 59 cycles of therapy against 0 in our series of 63 cycles. 
DISCUSSION 
Although 2 patients in this phase II study achieved a well 
documented major regression, ifosfamide seems to have minor 
activity in untreated patients with advanced adenocarcinoma of 
the oesophagus or oesophageal-gastric junction area. Such a 
lack of response has also been documented for epidermoid 
carcinoma of the oesophagus in two other trials [ 3, 41. However, 
we could not confirm the severe toxicity, especially myelosup- 
pression, described in these reports. Several factors could play a 
role in this discrepancy. For example, our patients had a better 
performance status than those described by Ansell et al. [3]. 
More than half of the patients in Nanus et aZ.‘s report were 
pretreated with radiotherapy and/or chemotherapy [4]. Concern- 
In conclusion, ifosfamide, given in a dose of 6 g/m2 over 
48 h, has a low activity as first-line treatment in patients with 
adenocarcinoma of the oesophagus. The application of a continu- 
ous administration over 48 h may result in a more favourable 
toxicity profile than observed in fractionated regimens using 
daily short intravenous infusions for several days. 
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Clinical Outcome of Postoperative Adjuvant 
Immunochemotherapy with Sizofiran for Patients 
with Resectable Gastric Cancer: a Randomised 
Controlled Study 
Shigeru Fujimoto, Hisashi Furue, Tadashi Kimura, Tatsuhei Kondo, 
Kunzo Orita, Tetsuo Taguchi, Koichi Yoshida and Nobuya Ogawa 
Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran (SPG), an extract from the culture 
broth of Schizophyllum commune Fries, was prescribed randomly for 386 Japanese patients with resectable 
gastric cancer. Although the overall survival probability for 5 years did not differ between the SPG and control 
groups, in 264 patients with curatively resected cancer, the probability to 5 year survival and to recurrence in the 
sizolkan-administered patients was better than in the controls. In the multivariate analysis, four of six prognostic 
factors correlated with the prognosis of the 264 patients who underwent curative surgery, that is, nodal 
involvement (x2 = 21.426, P = < O.OOOl), age distribution (x2 = 9.262, P = O.OlO), sizofiran administration 
(x2 = 6.507, P = O.Oll), and primary tumour size (x2 = 9.345, P = 0.025). Thus, patients with a curatively 
resected gastric cancer had a better prognosis when sizofiran was prescribed in combination with antitumour 
drugs. 
EurJ Cancer, Vol. 27, No. 9, pp. 1114-1118,199l. 
INTRODUCTION recurrence has to be given due consideration. For this purpose, 
WHILE AN early diagnosis of gastric cancer is now feasible, adjuvant cancer chemotherapy has been prescribed [l-3], but 
extensive resection has to be done for those in the advanced since anticancer drugs have immunosuppressive effects, adju- 
stage of the disease. The long-term survival of these patients vant immunotherapy is required to gain an extended time of 
depends on the extent of micrometastasis present at the time survival. 
of surgery, that is, the micrometastasis responsible for the Sizofiran (SPG), a glucan extracted from culture medium 
